Indications, dose adjustments and monitoring requirements for disease modifying drugs (DMDs) (licensed and unlicensed indications) included in this Framework are in line with national guidance published by the British Society for Rheumatology 2017. N.B. Mercaptopurine is not included in these 2017 guidelines, but monitoring requirements in this document are in line with those included for azathioprine.
